Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Medicaid Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Emergency Room Boarding
  • Device Coverage by Medicare
  • Planned Parenthood Funding
  • Covid/Flu Combo Shot
  • RFK Jr. vs. Congress

TRENDING TOPICS:

  • Emergency Room Boarding
  • Device Coverage by Medicare
  • Planned Parenthood Funding
  • Covid/Flu Combo Shot
  • RFK Jr. vs. Congress

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Wednesday, Sep 13 2023

Full Issue

Optimism For New Parkinson's Treatment; Recently Updated RCDI Treatments Are Promising

Read recent pharmaceutical developments in KFF Health News' Prescription Drug Watch roundup.

ScienceDaily: New Research Provides Hope For Parkinson's Disease Symptom Control 

Finding the right medication regimen to treat Parkinson's disease (PD) is a complex healthcare challenge. (Institute for Operations Research and the Management Sciences, 9/12)

CIDRAP: Breaking The Cycle: New Treatments For Recurrent C Diff (RCDI) Offer An Alternative To Repeated Antibiotics 

It's no secret that antibiotics are one of the foundations of modern medicine. Since penicillin was first introduced in the early 1940s, antibiotics have turned once-deadly infections into easily treatable conditions, made surgery and childbirth safer, enabled cancer patients to withstand immune system–sapping chemotherapy, and rendered organ transplants much less risky. But antibiotics don't come without their own risks. Just ask Pamela McCollister. (Dall, 9/11)

CIDRAP: New Protocols, Education Tied To Less Antibiotic Prescribing For Conjunctivitis

A multifaceted, quality improvement (QI) intervention at a Denver health system was associated with significantly reduced ophthalmic antibiotic prescribing for pediatric conjunctivitis, researchers reported yesterday in the Journal of the Pediatric Infectious Diseases Society. (Dall, 9/12)

Stat: Neurocrine Congenital Adrenal Hyperplasia Trial Succeeds 

Neurocrine Biosciences announced on Tuesday that an experimental drug for congenital adrenal hyperplasia succeeded in a late-stage trial, bringing the company a step closer to treating patients with a rare and serious set of genetic disorders that alters their ability to produce key hormones. (Wosen, 9/12)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, April 24
  • Thursday, April 23
  • Wednesday, April 22
  • Tuesday, April 21
  • Monday, April 20
  • Friday, April 17
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF